A number of other research firms have also recently issued reports on JNJ. The Goldman Sachs Group lifted their price target on Johnson & Johnson from $163.00 to $181.00 and gave the company a neutral rating in a report on Tuesday, April 12th. Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an outperform rating in a report on Wednesday, April 20th. Citigroup dropped their price objective on shares of Johnson & Johnson from $210.00 to $205.00 in a research note on Tuesday. Raymond James lifted their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an outperform rating in a research note on Wednesday, April 20th. Finally, Sanford C. Bernstein cut shares of Johnson & Johnson from an outperform rating to a market perform rating and boosted their target price for the company from $180.00 to $183.00 in a research report on Wednesday, March 16th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of Buy and an average target price of $187.86.
Shares of JNJ opened at $178.82 on Tuesday. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The firm has a 50-day moving average price of $178.30 and a 200 day moving average price of $170.66. The firm has a market capitalization of $470.55 billion, a PE ratio of 24.10, a P/E/G ratio of 2.92 and a beta of 0.66.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date of this dividend is Monday, May 23rd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.14%.
In other news, insider William Hait sold 29,699 shares of the firm’s stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total value of $5,452,142.42. Following the transaction, the insider now owns 80,236 shares in the company, valued at $14,729,724.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Thibaut Mongon sold 23,681 shares of Johnson & Johnson stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $176.25, for a total transaction of $4,173,776.25. The disclosure for this sale can be found here. 0.35% of the stock is owned by company insiders.
Hedge funds have recently made changes to their positions in the company. Family CFO Inc purchased a new position in Johnson & Johnson in the 4th quarter worth about $26,000. RE Dickinson Investment Advisors LLC raised its position in Johnson & Johnson by 163.3% in the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after buying an additional 98 shares during the last quarter. Advanced Research Investment Solutions LLC increased its position in shares of Johnson & Johnson by 200.0% during the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after purchasing an additional 120 shares during the last quarter. Steward Financial Group LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $34,000. Finally, Professional Financial Advisors LLC grew its stake in shares of Johnson & Johnson by 47.9% during the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after acquiring an additional 68 shares during the period. Hedge funds and other institutional investors own 68.78% of the company’s stock.
Johnson & Johnson Company Profile (Get Rating)
Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Time to Ride These 3 Mid Cap Momentum Plays
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.